跳转至内容
Merck
CN

ABE1950

Anti-DBC1 Antibody

from rabbit

别名:

Cell cycle and apoptosis regulator protein 2, Cell division cycle and apoptosis regulator protein 2, DBIRD complex subunit KIAA1967, Deleted in breast cancer gene 1 protein, DBC-1, DBC.1, p30 DBC, DBC1

登录 查看组织和合同定价。

选择尺寸


关于此项目

UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Anti-DBC1 Antibody, from rabbit

biological source

rabbit

conjugate

unconjugated

antibody form

purified antibody

antibody product type

primary antibodies

clone

polyclonal

species reactivity

human

technique(s)

ChIP: suitable
immunocytochemistry: suitable
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable

NCBI accession no.

UniProt accession no.

shipped in

wet ice

target post-translational modification

unmodified

Quality Level

Gene Information

human ... CCAR2(57805)

Analysis Note

Evaluated by Western Blotting in MCF7 cell lysate.

Western Blotting Analysis: 2.0 µg/mL of this antibody detected DBC1 in 10 µg of MCF7 cell lysate.

Application

Detect DBC1 using this Anti-DBC1 Antibody validated for use in Western Blotting, Immunoprecipitation, Immunocytochemistry, Immunohistochemistry, Chromatin Immunoprecipitation (ChIP).
Research Category
Epigenetics & Nuclear Function
Research Sub Category
Nuclear Receptors
Western Blotting Analysis: A representative lot detected DBC1 in HeLa cell lysate (Hiraike, H., et al. (2010). British Journal of Cancer. 102:1061-1067).
Western Blotting Analysis: A representative lot detected DBC1 in MDA-MB-231 cell lysate (Koyama, S., et al. (2010). BBRC. 392:357-362).
Immunoprecipitation Analysis: A representative lot immunoprecipitated DBC1 in HeLa cell lysate (Hiraike, H., et al. (2010). British Journal of Cancer. 102:1061-1067).
Immunocytochemistry Analysis: A representative lot detected DBC1 in MCF7 cells (Hiraike, H., et al. (2010). British Journal of Cancer. 102:1061-1067).
Immunocytochemistry Analysis: A representative lot detected DBC1 in MCF7 and T47D cells (Koyama, S., et al. (2010). BBRC. 392:357-362).
Immunohistochemistry Analysis: A representative lot detected DBC1 in ductal epithelium and adipose regions of human breast tissue sections (Hiraike, H., et al. (2010). British Journal of Cancer. 102:1061-1067).
Immunohistochemistry Analysis: A representative lot detected DBC1 in human breast cancer tissue (Hiraike, H., et al. (2011). Experimental and Therapeutic Medicane. 2:1105-1109).
Chromatin Immunoprecipitation (ChIP) Analysis: A representative lot detected DBC1 occupancy at the SIRT1 gene promoter region (1354–1902) known to be targeted by BRCA1 (Hiraike, H., et al. (2010). Br. J. Cancer. 102(6):1061-1067).

Biochem/physiol Actions

Expected to reacts with both spliced isoforms.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Cell cycle and apoptosis regulator protein 2 (UniProt Q8N163; also known as Cell division cycle and apoptosis regulator protein 2, DBC-1, DBC.1, DBIRD complex subunit KIAA1967, Deleted in breast cancer 1, p30 DBC, p30 DBC protein) is encoded by the CCAR2 (also known as DBC1, KIAA1967, NET35) gene (Gene ID 57805) in human. Deleted in breast cancer gene 1 protein (DBC1) is a nuclear protein involved in regulating functions of nuclear receptors (NRs), including androgen receptor (AR) and estrogen receptor (ER) alpha and beta. DBC1 stabilizes the interaction between chicken ovalbumin upstream promoter transcription factor I (COUP-TFI) and NCoR by interacting directly with both proteins. DBC1 also interacts with NR complex interacting factor (NRC)-1 to drive the transcription regulation of NRs. Caspase-dependent processing of DBC1 promotes apoptosis, and depletion of DBC1 negatively regulates p53-dependent apoptosis through its specific inhibition of SIRT1. The N-terimus of DBC1 is shown to interact with BRCA1 C-terminal BRCT domain and the expression of DBC1 represses BRCA1-mediated transactivation of the SIRT1 promoter. DBC1 is also a negative regulator against the ligand-dependent transcriptional activation function of ERbeta. The DBC1 protein encoded by the CCAR2 gene is not the same as the protein encoded by the BRINP1 gene, which also goes by the same acronym DBC1 for "Deleted in bladder cancer protein 1".
~130 kDa observed

Immunogen

GST-tagged recombinant protein corresponding to human DBC1.

Other Notes

Concentration: Please refer to lot specific datasheet.

Physical form

Format: Purified
Protein A purified
Purified rabbit polyclonal antibody in buffer containing PBS with 0.05% sodium azide.

Preparation Note

Stable for 1 year at 2-8°C from date of receipt.

未找到合适的产品?  

试试我们的产品选型工具.

存储类别

10 - Combustible liquids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

相关内容

A major focus of breast cancer research is to understand the mechanisms responsible for disease progression and drug resistance. Toward that end, it has been found that approximately two thirds of all human breast carcinomas overexpress the Estrogen Receptor α (ERα) protein and it remains the primary pharmacological target for endocrine therapy1,2. The normal cellular function of ERα is as a transcription factor that mediates a wide variety of physiological processes, many of which are dependent upon phosphorylation of the receptor at specific amino acid residues3,4. Indeed, ERα is known to be phosphorylated at a multitude of different sites, yet how these all correlate to disease remains unclear5. Here, we interrogated multiple sites of ERα for phosphorylation status by screening an extensive panel of different breast cancer patient samples and other non-breast cancer tissue microarray (TMA) slide samples to determine their relevance to disease.

Cancer is a complex disease manifestation. At its core, it remains a disease of abnormal cellular proliferation and inappropriate gene expression. In the early days, carcinogenesis was viewed simply as resulting from a collection of genetic mutations that altered the gene expression of key oncogenic genes or tumor suppressor genes leading to uncontrolled growth and disease (Virani, S et al 2012). Today, however, research is showing that carcinogenesis results from the successive accumulation of heritable genetic and epigenetic changes. Moreover, the success in how we predict, treat and overcome cancer will likely involve not only understanding the consequences of direct genetic changes that can cause cancer, but also how the epigenetic and environmental changes cause cancer (Johnson C et al 2015; Waldmann T et al 2013). Epigenetics is the study of heritable gene expression as it relates to changes in DNA structure that are not tied to changes in DNA sequence but, instead, are tied to how the nucleic acid material is read or processed via the myriad of protein-protein, protein-nucleic acid, and nucleic acid-nucleic acid interactions that ultimately manifest themselves into a specific expression phenotype (Ngai SC et al 2012, Johnson C et al 2015). This review will discuss some of the principal aspects of epigenetic research and how they relate to our current understanding of carcinogenesis. Because epigenetics affects phenotype and changes in epigenetics are thought to be key to environmental adaptability and thus may in fact be reversed or manipulated, understanding the integration of experimental and epidemiologic science surrounding cancer and its many manifestations should lead to more effective cancer prognostics as well as treatments (Virani S et al 2012).

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持